Mankind Pharma (MANKIND.NS) Stock Price

Mankind Pharma Price

NSE·CLOSED
2,516.40
​
Market closed

Over the last 7 years Mankind Pharma grew revenue by 16.2% annually, reaching 142.78 B INR. Earnings per share have grown at 18.6% per year over the last 7 years. For Mankind Pharma, the net margin of 13.4% is down versus 18.4% a few years ago. At today's price the dividend yield works out to roughly 0.04%. The payout ratio is around 2% of earnings. The consensus 12-month price target for Mankind Pharma is 2,606.10 INR, about 3.6% above where the stock trades today. Of 22 analysts, 16 rate the stock a buy — an overall Buy consensus.

Mankind Pharma stock price

Access this data via the Eulerpool API

Mankind Pharma business model & stock analysis

Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. The company is headquartered in New Delhi, Delhi and currently employs 18,468 full-time employees. The company went IPO on 2023-05-09. The firm is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The company has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.

Frequently asked questions about Mankind Pharma

Analysts currently set an average price target of 2,686.27 INR for the Mankind Pharma stock (median: 2,606.10 INR), implying +6.8 % versus the latest price. The consensus is based on 22 analyst ratings.

22 analysts currently rate the Mankind Pharma stock: 16 recommend buying, 4 holding and 2 selling.

Converted at the current exchange rate, the Mankind Pharma share trades at 23.24 EUR (2,516.40 INR).

The Mankind Pharma share (MANKIND.NS) is listed on 2 stock exchanges, including: NSE (Indien) (MANKIND.NS).

The revenue of Mankind Pharma is 142.78 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Mankind Pharma is 19.13 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Mankind Pharma is currently 54.39. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Mankind Pharma stock.

The price-to-sales ratio (P/S) of Mankind Pharma is currently 7.29. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Mankind Pharma stock.

The Eulerpool Quality Score for Mankind Pharma is 5/10.

The ISIN of Mankind Pharma is INE634S01028. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Mankind Pharma is MANKIND.NS. The ticker symbol is used to trade Mankind Pharma shares on the stock exchange.

Fair ValueTerminal
2,315.09 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
7.73 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
INR
Initial public offering
May 9, 2023
ISIN
INE634S01028
Cusip
Y57688114
Market capitalization
1.04 T INRMega Cap
52-Week Range
PEG
3.28
P/E ratio
P/Ee 2027
44.05
P/Ee 2028
35.74
P/Ee 2029
30.01
P/Ee 2030
23.84
P/S
P/Se
6.48
EV/EBIT
38.03
P/B Ratio
6.37
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
11.74 %
Last updated Oct 8, 2026, 11:53 AM

Mankind Pharma Peer Group

Mankind Pharma Ticker

BSE · MANKIND.BONSE INDIA · MANKIND.NS

Mankind Pharma FIGI

MANKIND:IN · BBG001BN0FY3MANKIND:IB · BBG01G9WXG92MANKIND:IS · BBG01G9WXGC8